BridgeBio Pharma Inc

BBIO: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
SWfLOCK|SDLOCK|WB&x&L

BridgeBio Earnings: Attruby Growth and Pipeline Updates Support Long-Term Outlook

BridgeBio reported $353 million in sales, up roughly 193% year over year, and ahead of FactSet consensus. Attruby (for ATTR-CM) sales contributed $253 million, up roughly 14% sequentially, reflecting physician uptake and new-patient adoption. Shares are up roughly 6% on Oct. 30.

Sponsor Center